Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) FCF Margin (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed FCF Margin for 5 consecutive years, with 73.64% as the latest value for Q2 2024.

  • On a quarterly basis, FCF Margin rose 246818.0% to 73.64% in Q2 2024 year-over-year; TTM through Mar 2025 was 9.45%, a 369829.0% increase, with the full-year FY2024 number at 3.12%, up 325795.0% from a year prior.
  • FCF Margin was 73.64% for Q2 2024 at Fulcrum Therapeutics, up from 2667.62% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 73.64% in Q2 2024 to a low of 8201.69% in Q1 2023.
  • A 5-year average of 1698.22% and a median of 862.35% in 2022 define the central range for FCF Margin.
  • Peak YoY movement for FCF Margin: plummeted -733935bps in 2023, then surged 246818bps in 2024.
  • Fulcrum Therapeutics' FCF Margin stood at 454.86% in 2020, then rose by 10bps to 409.27% in 2021, then tumbled by -603bps to 2876.2% in 2022, then grew by 7bps to 2667.62% in 2023, then skyrocketed by 103bps to 73.64% in 2024.
  • Per Business Quant, the three most recent readings for FULC's FCF Margin are 73.64% (Q2 2024), 2667.62% (Q4 2023), and 3026.48% (Q3 2023).